abbott.mediaroom

Abbott receives FDA approval for new CardioMEMS HF System capabilities that help patients engage in the care of their heart condition

For the first time, U.S. CardioMEMS patients will be able to view pulmonary artery pressure (PAP) readings and receive personalized medication updates through the CardioGuide HF App Rising PAP ...
abbott.mediaroom

Abbott introduces Ensure® Max Protein 3-in-1 Muscle Support, bringing the benefits of a supplement stack into one scoop

New powder combines 30 grams of high‑quality protein to help build muscle tissue,† 5 grams of creatine monohydrate to support ...
abbott.mediaroom

Abbott acquisition of Exact Sciences set to close on March 23, 2026

Announcement follows receipt of all regulatory clearances necessary for closing Transaction enables Abbott to enter and lead in fast-growing cancer screening and diagnostics segments, serving millions ...
abbott.mediaroom

Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes

Libre Duo 10 Day is a first-of-its-kind, two-in-one biowearable that monitors glucose and helps detect rising ketone levels that can lead to diabetic ketoacidosis (DKA), a serious health condition for ...
abbott.mediaroom

Abbott launches SimpleScreen™ CRC blood test, joining Cologuard Plus® in its colorectal cancer screening portfolio

Only Abbott offers a complete screening solution combining end-to-end support with both stool- and blood-based colorectal cancer screening options, giving healthcare providers more ways to help ...
abbott.mediaroom

Abbott Reports Second-Quarter 2025 Results

The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information." Reflects the net tax benefit associated with the ...
abbott.mediaroom

Abbott Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Financial Outlook

The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information." Restructuring and cost reduction initiative ...
abbott.mediaroom

Abbott Reports Third-Quarter 2025 Results and Reaffirms Full-Year Guidance

The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information." Restructuring and cost reduction initiative ...
abbott.mediaroom

Abbott Reports Fourth-Quarter and Full-Year 2023 Results; Issues 2024 Financial Outlook

The table above provides additional details regarding the specified items described on tables titled "Non-GAAP Reconciliation of Financial Information." a) Acquisition-related expenses include ...
abbott.mediaroom

Abbott Reports Third-Quarter 2023 Results and Raises Midpoint of Full-Year EPS Guidance Range

The table above provides additional details regarding the specified items described on tables titled "Non-GAAP Reconciliation of Financial Information". a) Acquisition-related expenses include ...
abbott.mediaroom

Abbott Reports Fourth-Quarter 2020 Results; Issues Strong Double-Digit Growth Forecast for 2021

2020 Tax expense on Earnings from Continuing Operations includes the recognition of approximately $135 million of tax benefits related to the impairment of certain assets, approximately $25 million of ...